Pulmonary Embolism Risk Stratification: PESI, sPESI, and Outpatient Management
Risk Stratification: PESI and Simplified PESI
The Pulmonary Embolism Severity Index (PESI) uses 11 clinical variables to stratify 30-day mortality risk into five classes. PESI classes I-II (low risk, 30-day mortality 1.0-3.5%) are candidates for abbreviated hospital stays or outpatient management. The simplified PESI (sPESI) assigns one point each for age >80, cancer, heart failure/chronic lung disease, heart rate ≥110, systolic BP <100 mmHg, and SpO2 <90%. An sPESI of 0 identifies low-risk patients with 30-day mortality of 1.0% (95% CI 0.0-2.1%), validated across multiple cohorts.
Right Ventricular Dysfunction Assessment
The 2019 ESC guidelines classify PE into massive (high-risk: hemodynamic instability), submassive (intermediate-risk: RV dysfunction and/or elevated troponin), and low-risk. RV dysfunction is assessed by CT angiography (RV/LV ratio >0.9), echocardiography (RV dilation, hypokinesis, McConnell sign, TAPSE <16 mm), or biomarkers (elevated troponin or NT-proBNP >600 pg/mL). Intermediate-risk PE is further subdivided: intermediate-high (both RV dysfunction AND elevated troponin) carries 7-11% short-term mortality, while intermediate-low (one or neither) carries 3-5%.
Outpatient PE Management: Hestia Criteria
The Hestia criteria provide a practical 11-item checklist to identify PE patients safe for home treatment. Exclusion criteria include hemodynamic instability, need for thrombolysis, active bleeding, oxygen requirement, PE diagnosed on anticoagulation, severe pain requiring IV analgesics, medical or social reasons for admission, CrCl <30 mL/min, severe liver disease, pregnancy, and history of HIT. The Hestia validation study (OTPE trial) demonstrated 0.4% VTE recurrence and 0% mortality at 3 months among 297 outpatient-managed PE patients meeting Hestia criteria.
Sponsored
Anticoagulation: DOAC-First Approach
DOACs are now first-line for PE anticoagulation. Rivaroxaban (15 mg BID x 21 days, then 20 mg daily) and apixaban (10 mg BID x 7 days, then 5 mg BID) offer single-drug approaches without parenteral bridging. The EINSTEIN-PE trial showed rivaroxaban non-inferior to enoxaparin/warfarin for recurrent VTE (HR 1.12, 95% CI 0.75-1.68) with less major bleeding (1.1% vs 2.2%). The AMPLIFY trial showed apixaban non-inferior for VTE recurrence with 69% less major bleeding (HR 0.31, 95% CI 0.17-0.55). Extended anticoagulation (beyond 3-6 months) should be considered for unprovoked PE, with DOACs at reduced doses (rivaroxaban 10 mg, apixaban 2.5 mg BID) supported by EINSTEIN-CHOICE and AMPLIFY-EXT data.
Intermediate-Risk PE: The Thrombolysis Debate
The PEITHO trial demonstrated that tenecteplase in intermediate-high-risk PE reduced hemodynamic decompensation by 56% (HR 0.44, 95% CI 0.23-0.87) but increased major bleeding (6.3% vs 1.2%) and hemorrhagic stroke (2.0% vs 0.2%), with no mortality benefit. This led to the current recommendation against routine systemic thrombolysis in hemodynamically stable PE, reserving it for clinical deterioration. Catheter-directed therapy (CDT) using reduced-dose tPA (ULTIMA trial: 10-20 mg over 15 hours) or aspiration thrombectomy represents an evolving alternative for intermediate-high-risk patients at low bleeding risk, though randomized evidence comparing CDT to anticoagulation alone remains limited.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.